J&J case: Government asks ‘victims’ to approach central or state panel

NEW DELHI: The government Tuesday issued a public notice stating that patients suffering from disability due to faulty articular surface replacement (ASR) hip implants can approach either the central expert committee or the state-level panel.

In case the affected patients intend to approach the central expert committee, they may write to the legal cell of the Central Drugs Standard Control Organisation, FDA Bhavan on Kotla Road, New Delhi.

They may send an email on legalcell@cdsco.nic.in.

If the affected patients approach the state-level committee, they may write to the concerned state drug controller who will be the member secretary of the state-level committee.

The Centre, earlier this month, constituted the central expert committee under the chairmanship of R K Arya, director of Sports Injury Centre at Safdarjung Hospital, to determine the quantum of compensation to be given to patients who have faulty hip implants, manufactured by DePuy International, a subsidiary of Johnson & Johnson.

Apart from the five-member expert panel, the Union Health Ministry has asked principle/health secretaries of all the states and the Union Territories to constitute separate committees so that they can receive such complaints from the affected patients.

The move came after a panel, constituted earlier by the Union Health Ministry to investigate complaints about articular surface replacement (ASR) hip implant devices, said in its report that the pharma giant “suppressed” facts on the harm of surgeries afterwards, which was conducted on patients in India using “faulty” hip replacement systems.

It had also suggested that the company pay compensation of around Rs 20 lakh to the affected patients. Some of the patients who had suffered due to the faulty implants had questioned the panel’s recommendation of the paltry amount, saying it was like “rubbing salt into their wounds”.

The Health Ministry, in its order dated August 30, has asked the central expert committee to submit its recommendation to the Central Drugs Standard Control Organisation (CDSCO) within 45 days of receiving recommendations from the state-level panels.

The order had said a committee under the chairmanship of Arun Kumar Aggarwal has given its report which has been accepted by the central government with certain modifications.

“Now the central government has decided to constitute a central expert committee to determine the quantum of compensation, as admissible under the law, in respect of faulty ASR hip implants manufactured by M/s DePuy International Limited, UK and implanted in India,” the had order said.

  • Related Posts

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Bharat Mandapam witnessed Spectacle of Crazy Innovations by Maker of Ssi Mantra, Best in class Surgical Robot New Delhi: It was a veritable display of innovative potential and prowess of…

    On World Health Day ‘CAHO Na Patient Se Pyaar Hai’

    Chennai hosts 3 Day International Conference CAHOCON on Patient Safety in Hospitals starting April 10 New Delhi:  Patient safety in hospitals is a global concern, more so in India. It…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    IPC releases draft NFI-2026 to promote rational use of medicines

    IPC releases draft NFI-2026 to promote rational use of medicines